IL‐6 is reported to restore the impaired accumulation of MDSCs and tumor progression in tumor‐bearing mice lacking IL‐1β or indoleamine 2,3‐dioxygenase (IDO; Bunt et al., 2007; Smith et al., 2012). The gene discussed is IDO2; the disease is neoplasm.